AZTA Stock Analysis: Azenta | NASDAQ
Medical Instruments & Supplies | NASDAQ, USA | Market Cap: 1.166m USD | 12M Return: -25.7% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 16.3M
EPS Trend: 79.9%
Qual. Beats: -2
Rev. Trend: -67.0%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Azenta, Inc. (NASDAQ: AZTA) provides biological and chemical compound sample exploration and management solutions for the life sciences industry, operating across the United States, China, the United Kingdom, Europe, and Asia Pacific. The company is headquartered in Burlington, Massachusetts, was founded in 1978, and was formerly known as Brooks Automation, Inc. before rebranding to Azenta in December 2021.
The business operates through two reportable segments. The Sample Management Solutions segment offers automated stores, cryogenic storage systems, automated sample tubes, consumables, instruments, controlled rate thawing devices, sample repository services, and consultation services that support clients across experimental design and implementation. These offerings serve biobanking, pharmaceutical, and academic research customers that require secure, temperature-controlled storage of biological materials.
The Multiomics segment provides genomic and other sample analysis services, including gene sequencing and gene synthesis, which support genomics research, drug discovery, and precision medicine workflows. Azenta also maintains a strategic partnership with Frontier Space Ltd to conduct scientific experiments in space.
- Bultiomics genomics services revenue growth drives margin expansion
- Life sciences R&D spending weakness pressures sample management orders
- China and Europe biopharma demand softness weighs on segment revenue
| Net Income: -178.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA -0.06 > 1.0 |
| NWC/Revenue: 78.75% < 20% (prev 83.63%; Δ -4.88% < -1%) |
| CFO/TA 0.03 > 3% & CFO 61.0m > Net Income -178.2m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.83 > 1.5 & < 3 |
| Outstanding Shares: last quarter (46.1m) vs 12m ago 0.72% < -2% |
| Gross Margin: 44.55% > 18% (prev 45.87%; Δ -1.32% > 0.5%) |
| Asset Turnover: 30.24% > 50% (prev 28.69%; Δ 1.55% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.25 (Total Current Assets 727.0m - Total Current Liabilities 257.2m) / Total Assets 1.90b |
| B: 0.65 (Retained Earnings 1.24b / Total Assets 1.90b) |
| C: -0.08 (EBIT TTM -149.7m / Avg Total Assets 1.97b) |
| D: 4.45 (Book Value of Equity 1.55b / Total Liabilities 349.2m) |
| Altman-Z'' = 7.91 = AAA |
| DSRI: 0.86 (Receivables 131.3m/149.5m, Revenue 596.6m/585.8m) |
| GMI: 1.03 (GM 45.87% / 44.55%) |
| AQI: 0.91 (AQ_t 0.50 / AQ_t-1 0.55) |
| SGI: 1.02 (Revenue 596.6m / 585.8m) |
| TATA: -0.13 (NI -178.2m - CFO 61.0m) / TA 1.90b) |
| Beneish M = -3.17 (Cap -4..+1) = AA |
As of July 11, 2026, the stock is trading at USD 25.36 with a total of 544,665 shares traded. Over the past week, the price has changed by -1.86%, over one month by +13.32%, over three months by +14.18% and over the past year by -25.74%.
Current recommended Stop Loss: 22.80 (which is 10.1% or 2.2 ATR below the current price).
Azenta has received a consensus analysts rating of 3.43. Therefore, it is recommended to hold AZTA.
- StrongBuy: 1
- Buy: 1
- Hold: 5
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 26.2 | 3.3% |
P/E Forward = 30.8642
P/S = 1.9543
P/B = 0.7658
P/EG = 0.5263
Revenue TTM = 596.6m USD
EBIT TTM = -149.7m USD
EBITDA TTM = -92.9m USD
Long Term Debt = unknown (none)
Short Term Debt = 7.78m USD (from shortTermDebt, last fiscal year)
Debt = 55.7m USD (from shortLongTermDebtTotal, last quarter) (leases 55.7m already included)
Net Debt = -324.8m USD (calculated: Debt 55.7m - CCE 380.5m)
Enterprise Value = 840.9m USD (1.17b + Debt 55.7m - CCE 380.5m)
Interest Coverage Ratio = unknown (Ebit TTM -149.7m / Interest Expense TTM 0.0)
EV/FCF = 29.28x (Enterprise Value 840.9m / FCF TTM 28.7m)
FCF Yield = 3.42% (FCF TTM 28.7m / Enterprise Value 840.9m)
FCF Margin = 4.81% (FCF TTM 28.7m / Revenue TTM 596.6m)
Net Margin = -29.86% (Net Income TTM -178.2m / Revenue TTM 596.6m)
Gross Margin = 44.55% ((Revenue TTM 596.6m - Cost of Revenue TTM 330.8m) / Revenue TTM)
Gross Margin QoQ = 42.84% (prev 42.86%)
Tobins Q-Ratio = 0.44 (Enterprise Value 840.9m / Total Assets 1.90b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 55.7m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -118.2m (EBIT -149.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.83 (Total Current Assets 727.0m / Total Current Liabilities 257.2m)
Debt / Equity = 0.04 (Debt 55.7m / totalStockholderEquity, last quarter 1.55b)
Debt / EBITDA = 3.50 (negative EBITDA) (Net Debt -324.8m / EBITDA -92.9m)
Debt / FCF = -11.31 (Net Debt -324.8m / FCF TTM 28.7m)
Total Stockholder Equity = 1.67b (last 4 quarters mean from totalStockholderEquity)
RoA = -9.03% (Net Income -178.2m / Total Assets 1.90b)
RoE = -10.69% (Net Income TTM -178.2m / Total Stockholder Equity 1.67b)
RoCE = -9.09% (EBIT -149.7m / Capital Employed (Total Assets 1.90b - Current Liab 257.2m))
RoIC = -7.28% (negative operating profit) (NOPAT -118.2m / Invested Capital 1.62b)
WACC = 10.76% (E(1.17b)/V(1.22b) * Re(11.27%) + D(55.7m)/V(1.22b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 11.27% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -42.22 | Cagr: -8.83%
[DCF] Terminal Value 65.65% ; FCFF base≈30.0m ; Y1≈27.5m ; Y5≈24.4m
[DCF] Fair Price = 13.04 (EV 276.3m - Net Debt -324.8m = Equity 601.2m / Shares 46.1m; r=10.76% [WACC]; 5y FCF grow -10.29% → 2.50% )
EPS Correlation: 79.89 | EPS CAGR: 26.21% | SUE: -4.0 | # QB: -2
Revenue Correlation: -66.98 | Revenue CAGR: -3.15% | SUE: -0.13 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.10 | Chg30d=-56.90% | Revisions=-57% | Analysts=5
EPS current Year (2026-09-30): EPS=0.38 | Chg30d=-50.26% | Revisions=-62% | GrowthEPS=-25.9% | GrowthRev=+1.1%
EPS next Year (2027-09-30): EPS=0.61 | Chg30d=-42.97% | Revisions=-38% | GrowthEPS=+62.4% | GrowthRev=+4.8%
[Analyst] Revisions Ratio: -71% (up=1, down=13)